On October 9, ImmunityBio, Inc. rose 5.05% in regular trading, trading at $10.41/share, with turnover of $16.54 million.

Within the Biotechnology sector where ImmunityBio, Inc. belongs, the overall sector change is positive. Among individual stocks, Moderna up 8.78%, Twist Bioscience up 6.81%, AbbVie up 1.08%, Gilead Sciences up 1.47%, Amgen up 0.87%.

ImmunityBio, Inc. is a leading late-stage immunotherapy company focused on activating the innate and adaptive immune systems to treat serious unmet needs in oncology and infectious diseases, with a comprehensive platform of natural killer cell therapies, antibody cytokine fusion proteins, and vaccine vectors.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)